These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25401338)

  • 21. Cytogenetic and molecular genetic alterations in hepatocellular carcinoma.
    Lau SH; Guan XY
    Acta Pharmacol Sin; 2005 Jun; 26(6):659-65. PubMed ID: 15916730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis.
    Midorikawa Y; Yamamoto S; Tsuji S; Kamimura N; Ishikawa S; Igarashi H; Makuuchi M; Kokudo N; Sugimura H; Aburatani H
    Hepatology; 2009 Feb; 49(2):513-22. PubMed ID: 19105209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis.
    Coulouarn C; Gomez-Quiroz LE; Lee JS; Kaposi-Novak P; Conner EA; Goldina TA; Onishchenko GE; Factor VM; Thorgeirsson SS
    Hepatology; 2006 Oct; 44(4):1003-11. PubMed ID: 17006931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.
    Yasui K; Konishi C; Gen Y; Endo M; Dohi O; Tomie A; Kitaichi T; Yamada N; Iwai N; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Tanaka S; Arii S; Itoh Y
    Cancer Sci; 2015 Jul; 106(7):929-37. PubMed ID: 25959919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma.
    Yuan BZ; Zhou X; Zimonjic DB; Durkin ME; Popescu NC
    J Mol Diagn; 2003 Feb; 5(1):48-53. PubMed ID: 12552080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury.
    Marhenke S; Buitrago-Molina LE; Endig J; Orlik J; Schweitzer N; Klett S; Longerich T; Geffers R; Sánchez Muñoz A; Dorrell C; Katz SF; Lechel A; Weng H; Krech T; Lehmann U; Dooley S; Rudolph KL; Manns MP; Vogel A
    Gut; 2014 Sep; 63(9):1501-12. PubMed ID: 24092862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early molecular and genetic determinants of primary liver malignancy.
    Feitelson MA; Pan J; Lian Z
    Surg Clin North Am; 2004 Apr; 84(2):339-54. PubMed ID: 15062649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
    Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
    Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B.
    Nosaka T; Naito T; Hiramatsu K; Ohtani M; Nemoto T; Marusawa H; Ma N; Hiraku Y; Kawanishi S; Yamashita T; Kaneko S; Nakamoto Y
    PLoS One; 2017; 12(10):e0185442. PubMed ID: 28968425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
    Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
    Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
    Yasui K; Arii S; Zhao C; Imoto I; Ueda M; Nagai H; Emi M; Inazawa J
    Hepatology; 2002 Jun; 35(6):1476-84. PubMed ID: 12029633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NOXIN as a cofactor of DNA polymerase-primase complex could promote hepatocellular carcinoma.
    Zhang ZZ; Huang J; Wang YP; Cai B; Han ZG
    Int J Cancer; 2015 Aug; 137(4):765-75. PubMed ID: 25612832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
    Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization.
    Marchio A; Meddeb M; Pineau P; Danglot G; Tiollais P; Bernheim A; Dejean A
    Genes Chromosomes Cancer; 1997 Jan; 18(1):59-65. PubMed ID: 8993981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepatocellular carcinoma.
    Furge KA; Dykema KJ; Ho C; Chen X
    BMC Genomics; 2005 May; 6():67. PubMed ID: 15882461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.
    Okamoto H; Yasui K; Zhao C; Arii S; Inazawa J
    Hepatology; 2003 Nov; 38(5):1242-9. PubMed ID: 14578863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease.
    Zimonjic DB; Ullmannova-Benson V; Factor VM; Thorgeirsson SS; Popescu NC
    Cancer Genet Cytogenet; 2009 May; 191(1):17-26. PubMed ID: 19389504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experimental observation on the alteration of metastatic potential and its gene function net of residual hepatocellular carcinoma following palliative liver resection].
    Huang XY; Huang ZL; Tang ZY; Xu B; Zheng Q; Zhou J; Wang L; Ye SL
    Zhonghua Yi Xue Za Zhi; 2010 May; 90(18):1278-82. PubMed ID: 20646604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy.
    Perugorria MJ; Castillo J; Latasa MU; Goñi S; Segura V; Sangro B; Prieto J; Avila MA; Berasain C
    Cancer Res; 2009 Feb; 69(4):1358-67. PubMed ID: 19190340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.